BI-1206 is under clinical development by BioInvent International and currently in Phase II for Sarcomas. According to GlobalData, Phase II drugs for Sarcomas have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BI-1206’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BI-1206 is under development for the treatment of solid tumors including non-small cell lung cancer, metastatic melanoma, B-cell lymphoma and leukemias such as chronic lymphocytic leukaemia, marginal zone B-cell lymphoma, follicular lymphoma, non-Hodgkin's lymphoma and mantle cell lymphoma and marginal zone lymphoma . It is administered as an intravenous infusion and subcutaneously. The therapeutic candidate is a fully human immunoglobulin G1 (IgG1) antagonistic monoclonal antibody of CD32b protein which is an immunosuppressive Fc gamma receptor IIB. The drug candidate is developed by using technology F.I.R.S.T which is based on antibody library n-CoDeR to identify several antibodies. It was also under development for the treatment of Waldenstrom macroglobulinemia.
BioInvent International overview
BioInvent International (BioInvent) focuses on the research and development of antibodies for the treatment of cancer. The company uses n-CoDeR, an inhouse platform for developing immuno-oncology drugs. n-CoDeR is an antibody library used for the rapid selection, screening and identification of antibodies. The company’s pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers. Titan has collaborations and partners with several leading pharmaceutical companies including Pfizer, MSD and Transgene for the co-development of its drug candidates. BioInvent is headquartered in Lund, Sweden.
For a complete picture of BI-1206’s drug-specific PTSR and LoA scores, buy the report here.